Introduction
============

FGF23 is produced by osteoblasts when they sense an increase in the serum concentration of phosphate.[@b1-ijnrd-11-125] FGF23 produced by the osteoblasts induces renal epithelial cells to promote phosphorus diuresis. Simultaneously, FGF23 suppresses the intake of phosphate in the intestinal tract by inhibiting production of the active form of vitamin D in renal epithelial cells.[@b2-ijnrd-11-125]--[@b4-ijnrd-11-125] Moreover, FGF23 plays an important role in the onset of chronic kidney disease--mineral and bone disorder.[@b5-ijnrd-11-125] Thus, FGF23 plays important roles in Ca--P metabolism. Recently, new physiological roles have been found for FGF23, such as the commitment of myocardium enlargement,[@b6-ijnrd-11-125] proliferation of chondrocytes,[@b7-ijnrd-11-125] infiltration of neutrophils[@b8-ijnrd-11-125] and impairment of B lymphopoiesis.[@b9-ijnrd-11-125] Furthermore, we have reported that FGF23 is expressed in the spleen, which plays important roles in the immune system, and the regulation of FGF23 expression in the spleen differs from that of the bone.[@b10-ijnrd-11-125] In the spleen, plasmacytoid dendritic cells produce FGF23 and mature B cells express the FGF23 coreceptor, Klotho, suggesting that FGF23 plays an immunological role.[@b11-ijnrd-11-125] These results suggest that, in renal epithelial cells, FGF23 might have biological roles in addition to Ca--P metabolism. However, such additional roles have not been identified before now. It has been thought that they would be difficult to determine using conventional methods.

In vitro experiments are required to analyze the roles of FGF23 other than Ca--P metabolism because the serum level of calcium and phosphate would be changed by FGF23 administration in vivo and would subsequently influence gene expression in other tissues, including renal tubule epithelial cells. The mouse renal tubule epithelial cell line, mIMCD3, is a representative cell line which is frequently used for experiments relating to renal tubule epithelial cells and has been reported to express Klotho.[@b12-ijnrd-11-125] We confirmed the expression of both Klotho and FGF receptor 1 in mIMCD3 cells ([Figure S1](#SD1-ijnrd-11-125){ref-type="supplementary-material"}), demonstrating that this cell line is suitable for investigating the effects of FGF23. The expression of erythropoietin receptor in mIMCD3 cells was as same as that of erythroblast.

Recently, using exhaustive gene expression analyses with DNA microarrays followed by bioinformatics analysis, new pathogenetic mechanisms have been identified in diseases such as systemic lupus erythematosus[@b13-ijnrd-11-125] and systemic juvenile idiopathic arthritis.[@b14-ijnrd-11-125] New abnormalities and biological functions were clarified, which could not be achieved using conventional methods. To identify new biological roles of FGF23 in renal epithelial cells, we comprehensively analyzed gene expression in mIMCD3 cells following stimulation with FGF23. We used DNA microarrays and bioinformatics tools to identify candidate transcription factors for regulating differentially expressed genes.

Methods
=======

Cell line and cell culture
--------------------------

mIMCD3 cells were purchased from Riken Cell Bank (Tsukuba, Japan) and cultured in Dulbecco's modified Eagle's medium/F12 medium supplemented with 10% fetal bovine serum (SH30079.03; Hyclone, Logan, UT, USA) at 37°C under 5% CO~2~.

Extraction of RNA from mIMCD3 cells with or without FGF23 stimulation
---------------------------------------------------------------------

mIMCD3 cells were stimulated with FGF23 for 4 h in order to identify not only those genes whose expression is induced by FGF23 but also those whose expression is suppressed through inhibitory mechanisms, such as microRNAs. The cells were cultured with or without 10 ng/mL FGF23 (2629FG; R&D Systems, Minneapolis, MN, USA)[@b15-ijnrd-11-125] for 4 h. Total RNA was then extracted using TRIzol reagents (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer's protocol. RNA was extracted from five replicate cultures in each treatment group. The concentration of extracted RNA was measured, and the quality was evaluated by electrophoresis.

Analysis of gene expression using DNA microarrays
-------------------------------------------------

To minimize variations in gene expression between replicate cultures, the RNA for microarray analysis was made by mixing 1 mg from each of the five replicates stimulated with FGF23. RNA from the five replicates not treated with FGF23 was mixed in the same way to make a control. The concentration and quality of these RNA preparations were determined using a Nanodrop ND-1000 spectrophotometer (Thermo Fisher Scientific) and an Agilent Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA), as recommended by Agilent Technologies. Linear T7-based amplification was performed using 100 ng of each RNA preparation. Total RNA was amplified and labeled with Cy3 or Cy5 using an Agilent Low Input Quick Amp Labeling Kit, Two-color (Agilent Technologies), following the manufacturer's instructions. Yields of cRNA and the dye-incorporation rate were measured using a Nanodrop ND-1000 spectrophotometer and an Agilent Bioanalyzer. Hybridization was performed according to the Agilent 60-mer oligo microarray processing protocol, using the Agilent Gene Expression Hybridization Kit (Agilent Technologies). The labeled cRNA probes were hybridized overnight (17 h at 65°C) to Agilent Whole Mouse Genome oligo microarrays 8 × 60 K (Design ID: 028005). After washing, the microarrays were scanned using a G2505C Microarray Scanner (Agilent Technologies), and signal values were calculated using Agilent software. The median and SD of the background fluorescence level were calculated, and the probe for which the fluorescence intensity was less than the median background plus 2 × SD was considered to be not expressed. The Cy3/Cy5 ratios of all spots on the microarrays were normalized using the global ratio median normalization method. Changes in gene expression were quantified using the ratio of fluorescence values with FGF23 stimulation to those without FGF23 stimulation, obtained by calculating the geometric mean of the Cy3/Cy5 ratio from two microarray hybridization experiments. Upregulated genes were identified as those showing a with-FGF23-to-without-FGF23 ratio of more than 1.5, and for which both fluorescence values were more than 30. This meant that the differences in fluorescence values with and without FGF23 were more than the background SD, 11. Downregulated genes were identified as those showing a with-FGF23-to-without-FGF23 ratio of less than 0.7, and again showing fluorescence values of more than 30 both with and without FGF23 stimulation.

Bioinformatics analysis
-----------------------

Bioinformatics analysis was conducted using oPOSSUM, version 3.0 (<http://opossum.cisreg.ca/oPOSSUM3>) to identify transcription factors that putatively regulate the differentially expressed genes.

Effects of FGF23 on gene expression induced by erythropoietin
-------------------------------------------------------------

mIMCD3 cells, on which the expression of EpoR was confirmed ([Figure S1](#SD1-ijnrd-11-125){ref-type="supplementary-material"}) and whose expression level of EpoR was as same as that of erythroblasts, were stimulated with 1 U/mL erythropoietin (959ME; R&D Systems),[@b16-ijnrd-11-125] with or without 10 ng/mL recombinant FGF23 protein, for 2 or 4 h at 37°C. After stimulation, cells were washed twice with medium. RNA was extracted using TRIzol reagents, as described above, and cDNA was synthesized from total RNA using a Transcriptor First-Strand cDNA synthesis Kit (Roche Diagnostics, Mannheim, Germany). qPCR assays for *Akt1s1* (Mm01203150_g1), *Ak4* (Mm00784745_g1), *Ankrd37* (Mm01344843_g1), *Bnip3* (Mm01275600_g1), *Cadps2* (Mm01137059_g1), *Krt17* (Mm00495207_g1), *Mgarp1* (Mm00471236_g1), *Mt1* (Mm00496660_g1), *Mt2* (Mm00809556_g1), *Pdk1* (Mm00554300_g1), *Pygl* (Mm01289790_g1), *Rgs16* (Mm00803317_g1), *Selenbp* (Mm01611432_g1), *Slc16a3* (Mm00446102_g1) and *Tmprss6* (Mm0055119_g1) were performed on an ABI 7500 System (Thermo Fisher Scientific) using TaqMan Gene Expression Assays (Thermo Fisher Scientific). *Gapdh* (Mm99999915_g1; Thermo Fisher Scientific) was used as a housekeeping gene to normalize expression values.

Western blot analysis of phosphorylated STAT1
---------------------------------------------

mIMCD3 cells were stimulated with 5 U/mL erythropoietin,[@b17-ijnrd-11-125] with or without recombinant FGF23 protein at a concentration of 10, 20 or 50 ng/mL, for 15 min at 37°C. After stimulation, cells were washed twice with medium. After protein extraction using M-PER (Thermo Fisher Scientific) and a protein inhibitor, the protein concentration was determined using a Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). A total of 10 µg protein and STAT1 control cell extracts (9173; Cell Signaling Technology, Danvers, MA, USA) were applied to each lane of polyacrylamide electrophoresis gels. After electrophoresis, proteins were transferred onto PVDF membranes using the Ezblot (AE-1460; ATTO Corp, Tokyo, Japan) reagent and a semi-dry blotting unit (WSE-4110 PoweredBLOT One; ATTO Corp) according to the manufacturer's instructions. Membranes were then blocked for 1 h at room temperature in a commercial blocking reagent (PVDF Blocking Reagent for Can Get Signal^®^; Toyobo, Osaka, Japan). After three washes with TBST, membranes were incubated with a rabbit anti-phospho-STAT1 antibody (7649S; Cell Signaling Japan, Tokyo, Japan) diluted in immunoreaction enhancer solution (1:1000, Can Get Signal Solution 1; Toyobo), overnight at 4°C. The membranes were washed three times with TBST and then incubated with horseradish peroxidase-conjugated donkey anti-rabbit IgG (ab16284; Abcam, Cambridge, UK) diluted in immunoreaction enhancer solution (1:5000, Can Get Signal Solution 2; Toyobo) for 1 h at room temperature. Membranes were then washed in TBST and processed following an enhanced chemiluminescence protocol (ECL Prime Western Blotting Detection Reagent; GE Healthcare, Little Chalfont, UK). Antibody binding was detected using a WSE-6100 LuminoGraph chemiluminescence imaging system (ATTO Corp), and was quantified using the CS Analyzer version 1.0.2 (ATTO Corp). Membranes were stripped using EzReprobe (ATTO Corp) and reprobed for GAPDH (1:1000, SC-25778; Santa Cruz Biotechnology, Dallas, TX, USA) as a protein loading control.

ERK mediation of the suppression of gene expression by FGF23
------------------------------------------------------------

An ERK inhibitor, FR180204,[@b18-ijnrd-11-125] was purchased from Cayman Chemical (15544; Ann Arbor, MI, USA). mIMCD3 cells were stimulated with 1 U/mL erythropoietin and/or 10 ng/mL FGF23 with or without 1 µM FR180204, for 2 h. After stimulation, RNA was extracted and gene expression was analyzed using qPCR, as described above.

Statistical analysis
--------------------

All values are expressed as the means ± SD, and statistical significance was determined using the Kruskal--Wallis analysis of variance followed by the post hoc Steel--Dwas test. All statistical computations were performed using JMP version 13.0 (SAS Institute Inc, Cary, NC, USA). *p* \< 0.05 was considered statistically significant.

Results
=======

Microarray analysis of gene expression induced by FGF23
-------------------------------------------------------

DNA microarray analysis revealed that 26 genes were differentially expressed in mIMCD3 cells following FGF23 stimulation, compared with the same cells without FGF23 stimulation. The microarray data can be found on Gene Expression Omnibus (<https://www.ncbi.nlm.nih.gov/geo/>, GSE100847). Eight out of 26 genes were upregulated, and the remaining 18 were downregulated. Three out of eight upregulated genes were protein-coding genes ([Table 1](#t1-ijnrd-11-125){ref-type="table"}), and the remaining five were nonprotein coding ([Table 2](#t2-ijnrd-11-125){ref-type="table"}). Fifteen out of 18 downregulated genes were protein coding ([Table 1](#t1-ijnrd-11-125){ref-type="table"}), and the remaining three were nonprotein coding ([Table 2](#t2-ijnrd-11-125){ref-type="table"}). Three out of 15 downregulated protein-coding genes were identified as RIKEN genes, for which we could not perform expression analysis using qPCR.

Transcription factors putatively regulating differentially expressed genes
--------------------------------------------------------------------------

To identify mechanisms regulating gene expression, we performed a bioinformatics analysis to identify transcription factors with putative binding sites in the genes that were differentially expressed following FGF23 stimulation. Among the transcription factors with binding sites in FGF23-upregulated genes ([Table 3](#t3-ijnrd-11-125){ref-type="table"}), PPARγ and STAT3 were of greatest interest because they are known to be active in renal tubule epithelial cells. PPARγ mediates vitamin D activity in these cells.[@b19-ijnrd-11-125] STAT3 mediates the intracellular signaling of erythropoietin,[@b20-ijnrd-11-125] which is known to have effects on renal tubule epithelial cells, as well as protective effects on renal injury in patients with chronic kidney diseases.[@b21-ijnrd-11-125] The other transcription factors with binding sites in FGF23-upregulated genes are not known to act in renal tubule epithelial cells.

Among the transcription factors with binding sites in FGF23-downregulated genes ([Table 4](#t4-ijnrd-11-125){ref-type="table"}), STAT1 was of greatest interest because it is also known to mediate the intracellular signaling of erythropoietin.[@b20-ijnrd-11-125] The other transcription factors with binding sites in FGF23-downregulated genes are not known to act in renal tubule epithelial cells. These results suggest the possibility of cross talk between FGF23 and erythropoietin signaling in renal tubule epithelial cells.

FGF23 modulation of gene expression induced by erythropoietin in renal tubule epithelial cells
----------------------------------------------------------------------------------------------

As determined by qPCR, the expression of *Rgs16* tended to be upregulated following FGF23 stimulation for 2 h but was not significantly upregulated by FGF23 stimulation for 4 h. The expression of *Krt17* and *Akt1s1* was upregulated by FGF23 stimulation as determined using microarry analysis but not using qPCR. These differences could be attributable to the methods used, with the microarray analysis making a direct comparison, whereas the qPCR made an indirect comparison using a reference gene. The direct comparison is more reliable, according to a previous report.[@b22-ijnrd-11-125] Expression of *Rgs16*, which tended to be upregulated in response to FGF23, was also upregulated following erythropoietin stimulation ([Figure 1](#f1-ijnrd-11-125){ref-type="fig"}).

The expression of *Ak4*, *Ankrd37*, *Mgarp1*, *Slc16a3* and *Tmprss6* was significantly downregulated following FGF23 stimulation for 4 h. The expression of *Mt1*, *Mt2*, *Pdk1* and *Selenbp* tended to be downregulated by FGF23 stimulation for 4 h, but these effects were not significant. Expressions of remaining genes, *Bnip3*, *Cadps2*, *Mt1*, and *Pygl*, were downregulated by FGF23 stimulation for 4 h, as determined using microarray analysis, but not using qPCR. As described above, these differences could be attributable to the use of direct comparisons in the microarray analysis versus the less reliable indirect comparisons by qPCR. Moreover, the expression of *Bnip3*, *Cadps2*, *Mt2*, and *Pygl*, which were not significantly downregulated by FGF23 stimulation for 4 h, was significantly downregulated following stimulation for 2 h. The expression of *Mt1* tended to be downregulated following 2 h FGF23 stimulation. Thus, the downregulation of all genes identified using microarray analysis was confirmed using qPCR for either the 2 h or the 4 h FGF23 stimulation timepoint.

The expression of 10 out of 12 FGF23-downregulated genes was upregulated in response to erythropoietin ([Figure 2](#f2-ijnrd-11-125){ref-type="fig"}). According to our bioinformatics analysis, five of the 10 genes, *Bnip3*, *Mt1*, *Mt2*, *Pdk1* and *Slc16a3*, were related to oxidative stress, *Cadps2* was related to neurotransmission, *Pygl* was related to glycogenosis, *Selenbp* was related to cancer and *Tmprss6* was related to androgen signaling. Thus, FGF23 mainly modulated the oxidative stress genes induced by erythropoietin. The effects of erythropoietin on these genes were mediated by STAT1, as shown by the results of an STAT1 knock-down experiment ([Figure S2](#SD2-ijnrd-11-125){ref-type="supplementary-material"}). However, STAT1 phosphorylation was not significantly affected by FGF23 ([Figure 3](#f3-ijnrd-11-125){ref-type="fig"}). Expression of the 10 erythropoietin-upregulated genes was suppressed when the cells were stimulated with FGF23 and erythropoietin together ([Figure 2](#f2-ijnrd-11-125){ref-type="fig"}). These results indicate that FGF23 modulated the effects of erythropoietin in renal tubule epithelial cells in a STAT1-independent manner and illustrate cross talk between FGF23 and erythropoietin signaling.

ERK mediation of the effects of FGF23 on gene expression induced by erythropoietin
----------------------------------------------------------------------------------

ERK is known to mediate the induction of gene expression by FGF23.[@b15-ijnrd-11-125] To investigate whether it also mediates the suppressive effects of FGF23 on the induction of gene by erythropoietin, mIMCD3 cells were costimulated with erythropoietin, FGF23 and an ERK inhibitor. The expression of seven out of 10 erythropoietin-upregulated genes that were suppressed by FGF23, *Ankrd37*, *Mgarp1*, *Mt1*, *Mt2*, *Pygl*, *Slc16a3* and *Selenbp*, was significantly recovered following cotreatment with the ERK inhibitor ([Figure 4](#f4-ijnrd-11-125){ref-type="fig"}). Taken together, our results indicate that the mechanism by which FGF23 suppresses the induction of gene expression by erythropoietin might involve inhibitory RNAs that are induced through ERK activation by FGF23.

Discussion
==========

The role of FGF23 has mostly been studied in the field of Ca--P metabolism; however, other biological roles of FGF23 have been reported more recently. Thus, we hypothesized that FGF23 may have biological roles in renal cells other than Ca--P metabolism. To identify new biological roles of FGF23 in renal tubule epithelial cells, we performed an exhaustive gene expression analysis using DNA microarrays and bioinformatics analysis. As a result, PPARγ and STAT3 were identified as candidate transcription factors for mediating the upregulation of genes by FGF23. Conversely, STAT1 was identified as a candidate for mediating the downregulation of genes by FGF23. STAT1 and STAT3 are also known to mediate the intracellular signaling of erythropoietin. Erythropoietin is known to be involved in the restoration of renal function in patients with renal failure, and its receptor is expressed on renal tubule epithelial cells.[@b19-ijnrd-11-125] Thus, signaling through STAT1 is important in renal epithelial cell function. These observations suggest that FGF23 and erythropoietin might interact to regulate gene expression in renal tubule epithelial cells.

Indeed, we found that the expression of several genes that were downregulated by FGF23 was upregulated by erythropoietin. Furthermore, inhibition of ERK, which mediates FGF23 signaling, reversed the effects of FGF23 on erythropoietin-induced genes. Thus, FGF23 generally suppressed the biological activity of erythropoietin in renal tubule epithelial cells. Only one gene, *Rgs16*, was upregulated by both ligands. Therefore, FGF23 may not exclusively suppress gene expression induced by erythropoietin but also stimulate the expression of some erythropoietin-induced genes.

The physiological roles of erythropoietin in renal tubule epithelial cells have been reported to include the suppression of fibrosis, protection against apoptosis,[@b23-ijnrd-11-125] prevention of renal injury[@b24-ijnrd-11-125] and responses to oxidative stress.[@b25-ijnrd-11-125] These effects can act to prevent the injury of renal tubule epithelial cells. In this study, we showed that FGF23 modulated the expression of genes related to oxidative stress, *Mt1*, *Mt2*, *Ak4*, *Bnip3* and *Pdk1*,[@b26-ijnrd-11-125]--[@b30-ijnrd-11-125] which were induced by erythropoietin, but not the expression of genes related to other effects of erythropoietin, such as the suppression of fibrosis or apoptosis and the prevention of ischemic injury. Moreover, expression of the oxidative stress gene, *Nrf2*,[@b31-ijnrd-11-125] which has been reported to have protective effects against renal tubule cell injury, was not suppressed by FGF23. Furthermore, not all genes related to oxidative stress have a protective effect against renal tubule epithelial cell injury, because *Nupr1*, another gene related to oxidative stress, can act to potentiate the injury of renal tubule epithelial cells.[@b32-ijnrd-11-125] In light of these considerations, FGF23 may cooperate with erythropoietin to protect renal tubule epithelial cells against injury by suppressing the expression of oxidative stress genes that would have harmful effects if induced by erythropoietin alone. We aim to test this hypothesis in a future study.

We also found that erythroblasts expressed both EpoR and Klotho ([Figure 5](#f5-ijnrd-11-125){ref-type="fig"}). This observation similarly may be attributable to the interaction of erythropoietin and FGF23 in these cells. It may cause the erythropoietin-resistant anemia seen in patients with renal failure, whose serum levels of FGF23 are extremely high.[@b33-ijnrd-11-125]

According to our Western blot analysis, FGF23 did not influence the STAT1 phosphorylation that was induced by erythropoietin. Thus, FGF23 would not directly affect STAT1 activity. A possible alternative mechanism of FGF23--erythropoietin cross talk involves both signaling pathways acting directly on the promoters of target genes. Recently, there have been reports that nonprotein-coding genes can act as regulatory elements to suppress the expression of protein-coding genes.[@b34-ijnrd-11-125],[@b35-ijnrd-11-125] In this study, the expression of five nonprotein-coding genes was upregulated by FGF23. Thus, the mechanism of cross talk between FGF23 and erythropoietin might involve these regulatory nonprotein-coding genes. We have not yet clarified which nonprotein-coding genes are involved, but we would like to address this in a future study.

There were some limitations to this study. One is that by changing the criteria for identification of upregulated or downregulated genes, other meaningful genes might be discovered. Another is that the available bioinformatics data are increasing all the time, but we were only able to use the bioinformation accumulated to date. Hence, additional transcription factors may be identifiable in similar studies conducted in the future. Furthermore, the transcription factors identified in this study other than PPARγ, STAT1 and STAT3 may have important biological roles in renal epithelial cells, which should be clarified in future studies. The last is that we examined only one renal tubule epithelial cell line. Thus, different results may be obtained using cell lines other than mIMCD3.

Conclusion
==========

In summary, we attempted to identify new biological roles of FGF23 in renal tubule epithelial cells. Our results raise the possibility of cross talk between FGF23 and erythropoietin signaling. Because FGF23 and erythropoietin play important roles in the pathology of patients with chronic renal failure, elucidation of such cross talk could contribute to a better understanding of this pathological condition.

Supplementary materials
=======================

###### 

The mouse renal epithelial cell line, mIMCD3, expressing Klotho, FGFR1 and EpoR protein.

**Notes:** To confirm that mouse renal epithelial cell line, mIMCD3, expressed Klotho, FGFR1 and EpoR, the cells were assayed by flow cytometry. Aliquots of 10^6^ mIMCD3 cells were incubated with anti-Klotho/PE and anti-FGFR1/Alexa Fluor 647 antibodies, and anti-EpoR/FITC antibodies, and the cells were analyzed on an FACS Aria flow cytometer (BD Biosciences, San Jose, CA, USA): (**A**) isotype controls. (**B**) Klotho^+^ FGFRI^+^ gated. (**C**) Klotho^+^ FGFRI^+^ gated, EpoR. (**D**) Klotho^+^ FGFRI^+^ gated, isotype controls. PE was conjugated to anti-human Klotho monoclonal antibodies (cat. no. KO603) using a Phycoerythrin Labeling Kit-NH2 (Dojindo Molecular Technologies, Kumamoto, Japan). Alexa Fluor 647 was conjugated to anti-FGFR1 (cat. no. M19B2) using an Alexa Fluor 647 Microscale Protein Labeling Kit (Thermo Fisher Scientific, Waltham, MA, USA). FITC was conjugated to anti-mouse EpoR monoclonal antibodies (cat. no. ab56310) using a Fluorescein Labeling Kit-NH2 (Dojindo Molecular Technologies).

**Abbreviations:** FITC, fluorescein isothiocyanate; PE, phycoerythrin.

###### 

Effects of STAT1 knockdown on the upregulation of genes by erythropoietin.

**Notes:** A knockdown construct for STAT1 was purchased from GeneCopoeia (Rockville, MD, USA). The STAT1 knockdown sequence was inserted into the pcDNA3.1 vector (Thermo Fisher Scientific, Waltham, MA, USA). pcDNA3.1, either with or without the STAT1 knockdown sequence, was transferred into mIMCD3 cells. These cells were then stimulated with 1 U/mL erythropoietin, for either 2 or 4 h. RNA was extracted, and gene expression was analyzed using quantitative polymerase chain reactions, as described in the "Materials and methods" section. The expression of *Bnip3*, *Cadps2*, *Mgarpl*, *Mtl*, *Pygl* and Selenbp was correlated with that of STAT1, suggesting that the induction of these genes was mediated by STAT1. For each gene, the line-of-best-fit showing the correlation with STAT1 expression is shown. Black circles: cells treated with pcDNA3.1 without the STAT1 knockdown sequence; white squares: cells treated with pcDNA3.1 with the STAT1 knockdown sequence.
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![Interactive effects of FGF23 and erythropoietin on the expression of genes upregulated by FGF23.\
**Notes:** mIMCD3 cells were stimulated with erythropoietin with or without FGF23 for 2 or 4 h. Gene expression was measured by quantitative polymerase chain reactions. White bars: no stimulation; black bars: stimulation with 1 U/mL erythropoietin; vertically striped bars: stimulation with 10 ng/mL FGF23; horizontally striped bars: stimulation with 1 U/mL erythropoietin plus 10 ng/mL FGF23. n = 7--10. \**p* \< 0.05.\
**Abbreviation:** ns, not significant.](ijnrd-11-125Fig1){#f1-ijnrd-11-125}

![Interactive effects of FGF23 and erythropoietin on the expression of genes downregulated by FGF23.\
**Notes:** mIMCD3 cells were stimulated with erythropoietin with or without FGF23 for 2 or 4 h. Gene expression was measured by quantitative polymerase chain reactions. White bars: no stimulation; black bars: stimulation with 1 U/mL erythropoietin; vertically striped bars: stimulation with 10 ng/mL FGF23; horizontally striped bars: stimulation with 1 U/mL erythropoietin plus 10 ng/mL FGF23. n = 7--10. \**p* \< 0.05.\
**Abbreviation:** ns, not significant.](ijnrd-11-125Fig2){#f2-ijnrd-11-125}

![Effect of FGF23 on the phosphorylation of STAT1 induced by erythropoietin.\
**Notes:** mIMCD3 cells were stimulated with the following: 5 U/mL erythropoietin alone; 10 ng/mL FGF23 alone or 5 U/mL erythropoietin plus 10, 20 or 50 ng/mL FGF23. Phosphorylated STAT1 was detected by Western blotting.\
**Abbreviations:** PC, positive control for phosphorylated STAT1 (control cell extract); none, unstimulated cells; Epo, erythropoietin; p-STAT1, phosphorylated STAT1; GAPDH, control for total protein loading.](ijnrd-11-125Fig3){#f3-ijnrd-11-125}

![Effects of ERK inhibition on the regulation of gene expression by FGF23 and erythropoietin.\
**Notes:** mIMCD3 cells were treated with erythropoietin alone, with erythropoietin plus FGF23 or with erythropoietin and FGF23 plus the ERK inhibitor, FR180204, for 2 h. Gene expression was measured by quantitative polymerase chain reactions. White bars: no treatment; black bars: 1 U/mL erythropoietin alone (E); vertically striped bars: 1 U/mL erythropoietin plus 10 ng/mL FGF23 (EF); horizontally striped bars: 1 U/mL erythropoietin and 10 ng/mL FGF23 plus 1 µM FR180204 (FR + EF). n = 6. \**p* \< 0.05.](ijnrd-11-125Fig4){#f4-ijnrd-11-125}

![Expression of EpoR and Klotho protein by mouse bone marrow cells.\
**Notes:** To confirm that mouse bone marrow cells expressed EpoR and Klotho, these cells were assayed by flow cytometry. Aliquots of 10^6^ bone marrow cells were incubated with anti-EpoR--FITC and anti-Klotho--PE antibodies, and the cells were analyzed on an FACS Aria flow cytometer (BD Biosciences, San Jose, CA, USA). (**A**) Erythroblast gating (P1) of bone marrow cells (FSC-A, SSC-A). (**B**) P1 gated, isotype controls. (**C**) P1 gated, EpoR- and Klotho-labeled. Bone marrow cells were obtained from the femurs and tibias of male C57BL/6J mice. PE was conjugated to an anti-human Klotho monoclonal antibody (cat. no. KO603) using a Phycoerythrin Labeling Kit-NH2 (Dojindo Molecular Technologies, Kumamoto, Japan). FITC was conjugated to an anti-mouse EpoR monoclonal antibody (cat. no. ab56310) using a Fluorescein Labeling Kit-NH2 (Dojindo Molecular Technologies).\
**Abbreviations:** FITC, fluorescein isothiocyanate; PE, phycoerythrin; FSC-A, forward scatter; SSC-A, side scatter.](ijnrd-11-125Fig5){#f5-ijnrd-11-125}

###### 

Differentially expressed protein-coding genes following FGF23 stimulation

  Gene symbol               Gene title                                                                                                                                              Accession no.   Fold change
  ------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------- --------------- -------------
  **Upregulated genes**                                                                                                                                                                             
  *Rgs16*                   ref\|Mus musculus regulator of G-protein signaling 16                                                                                                   NM_011267       1.514
  *Krt17*                   ref\|Mus musculus keratin 17                                                                                                                            NM_010663       1.509
  *Akt1s1*                  ref\|Mus musculus AKT1 substrate 1 (proline-rich), transcript variant 3                                                                                 NM_001290694    1.529
  **Downregulated genes**                                                                                                                                                                           
  *Bnip3*                   ref\|Mus musculus BCL2/adenovirus E1B-interacting protein 3                                                                                             NM_009760       0.460
  *Ak4*                     ref\|Mus musculus adenylate kinase 4, transcript variant 1                                                                                              NM_001177602    0.666
  *Mt1*                     ref\|Mus musculus metallothionein 1                                                                                                                     NM_013602       0.565
  *Mt2*                     ref\|Mus musculus metallothionein 2                                                                                                                     NM_008630       0.575
  *Pdk1*                    ref\|Mus musculus pyruvate dehydrogenase kinase, isoenzyme 1                                                                                            NM_172665       0.619
  *Slc16a3*                 ref\|Mus musculus solute carrier family 16 (monocarboxylic acid transporters), member 3                                                                 NM_030696       0.654
  *Cadps2*                  ref\|Mus musculus Ca^2+^-dependent activator protein for secretion 2, transcript variant 1                                                              NM_153163       0.602
  *Tmprss6*                 ref\|Mus musculus transmembrane serine protease 6                                                                                                       NM_027902       0.649
  *Selenbp1*                ref\|Mus musculus selenium-binding protein 1                                                                                                            NM_009150       0.621
  *Ankrd37*                 ref\|Mus musculus ankyrin repeat domain 37                                                                                                              NM_001039562    0.624
  *2010300C02Rik*           ref\|Mus musculus RIKEN cDNA 2010300C02 gene                                                                                                            NM_028096       0.669
  *9530097N15Ri*            gb\|Mus musculus adult male urinary bladder cDNA, RIKEN full-length enriched library, clone: 9530097N15 product: unclassifiable, full insert sequence   AK020664        0.619
  *1700026L06Rik*           ref\|Mus musculus RIKEN cDNA 1700026L06 gene                                                                                                            NM_027283       0.648

###### 

Differentially expressed noncoding genes following FGF23 stimulation

  Gene symbol                  Gene title                                        Affymetrix probe ID   Fold change
  ---------------------------- ------------------------------------------------- --------------------- -------------
  **Upregulated genes**                                                                                
  chr11:58136882-58143829_R    lincRNA:chr11:58136882-58143829 reverse strand    10094                 1.647
  chr11:58136882-58143829_R    lincRNA:chr11:58136882-58143829 reverse strand    17372                 1.950
  chr1:59775022-59780348_F     lincRNA:chr1:59775022-59780348 forward strand     51425                 1.561
  chr9:95295459-95301266_F     lincRNA:chr9:95295459-95301266 forward strand     56437                 1.514
  chr11:58136882-58143829_R    lincRNA:chr11:58136882-58143829 reverse strand    61180                 2.038
  **Downregulated genes**                                                                              
  chr4:56013597-56020622_R     lincRNA:chr4:56013597-56020622 reverse strand     44012                 0.661
  A_55_P2097048                Unknown                                           54292                 0.468
  chr6:112552041-112560067_R   lincRNA:chr6:112552041-112560067 reverse strand   59856                 0.572

###### 

Transcription factors putatively involved in the upregulation of genes following FGF23 stimulation

  Transcription factor   JASPAR ID   No. of target gene hits   Hit genes         Biological function
  ---------------------- ----------- ------------------------- ----------------- ---------------------
  Zfp423                 MA0116.1    2                         *Krt17, Akt1s1*   Zinc-finger
  RORA_1                 MA0071.1    2                         *Krt17, Akt1s1*   Immunity
  PPARG::RXRA            MA0065.2    2                         *Krt17, Akt1s1*   Vitamin D
  Spz1                   MA0111.1    2                         *Krt17, Akt1s1*   Sex determination
  INSM1                  MA0155.1    2                         *Krt17, Akt1s1*   Zinc-finger
  CREB1                  MA0018.2    2                         *Krt17, Akt1s1*   Neurons
  Stat3                  MA0144.1    2                         *Krt17, Akt1s1*   Erythropoietin
  REL                    MA0101.1    2                         *Krt17, Akt1s1*   NF-κb signaling
  EBF1                   MA0154.1    2                         *Krt17, Akt1s1*   Immunity
  SP1                    MA0079.2    2                         *Krt17, Akt1s1*   Zinc-finger
  YY1                    MA0095.1    2                         *Krt17, Akt1s1*   Immunity
  MZF1_5-13              MA0057.1    2                         *Krt17, Akt1s1*   Zinc-finger
  ELK1                   MA0028.1    2                         *Krt17, Akt1s1*   ERK signaling
  Klf4                   MA0039.2    2                         *Krt17, Akt1s1*   Cancer
  NFATC2                 MA0152.1    2                         *Krt17, Akt1s1*   Immunity
  Arnt::Ahr              MA0006.1    2                         *Krt17, Akt1s1*   Inflammation

###### 

Transcription factors putatively involved in the downregulation of genes following FGF23 stimulation

  Transcription factor   JASPAR ID   No. of target gene hits   Hit genes                                                                                                  Biological function
  ---------------------- ----------- ------------------------- ---------------------------------------------------------------------------------------------------------- ---------------------
  HOXA5                  MA0158.1    12                        *Ak4, Ankrd37, Bnip3, Cadps2, Mt1, Pdk1, Pygl, Selenbp1, Slc16a3, Tmprss6, 1700026L06Rik, 2010300C02Rik*   Fat metabolism
  Pdx1                   MA0132.1    10                        *Ak4, Ankrd37, Cadps2, Mt1, Pdk1, Selenbp1, Slc16a3, Tmprss6, 1700026L06Rik, 2010300C02Rik*                Organogenesis
  ZEB1                   MA0093.1    10                        *Ak4, Ankrd37, Bnip3, Cadps2, Pdk1, Pygl, Slc16a3, Tmprss6, 1700026L06Rik, 2010300C02Rik*                  Organogenesis
  HIF1A ARNT             MA0259.1    9                         *Ak4, Ankrd37, Bnip3, Cadps2, Pdk1, Slc16a3, Tmprss6, 1700026L06Rik, 2010300C02Rik*                        Oxidative stress
  NFATC2                 MA0152.1    9                         *Ak4, Ankrd37, Cadps2, Pdk1, Pygl, Slc16a3, Tmprss6, 1700026L06Rik, 2010300C02Rik*                         Immunity
  Nkx2-5                 MA0063.1    9                         *Ak4, Ankrd37, Bnip3, Cadps2, Pygl, Selenbp1, Tmprss6, 1700026L06Rik, 2010300C02Rik*                       Organogenesis
  SPIB                   MA0081.1    9                         *Ak4, Ankrd37, Cadps2, Pdk1, Pygl, Slc16a3, Tmprss6, 1700026L06Rik, 2010300C02Rik*                         Organogenesis
  USF1                   MA0093.1    8                         *Ak4, Ankrd37, Bnip3, Cadps2, Pdk1, Slc16a3, 1700026L06Rik, 2010300C02Rik*                                 Fat metabolism
  Arnt                   MA0004.1    8                         *Ak4, Ankrd37, Bnip3, Cadps2, Pdk1, Slc16a3, 1700026L06Rik, 2010300C02Rik*                                 Oxidative stress
  FOXO3                  MA0157.1    7                         *Ak4, Cadps2, Pdk1, Pygl, Slc16a3, Tmprss6, 1700026L06Rik*                                                 Organogenesis
  Prrx2                  MA0075.1    7                         *Ankrd37, Cadps2, Pdk1, Selenbp1, Slc16a3, Tmprss6, 2010300C02Rik*                                         Organogenesis
  SRY                    MA0084.1    7                         *Ankrd37, Cadps2, Pdk1, Pygl, Slc16a3, 1700026L06Rik, 2010300C02Rik*                                       Sex determination
  Sox5                   MA0087.1    7                         *Ak4, Ankrd37, Cadps2, Pdk1, Selenbp1, 1700026L06Rik, 2010300C02Rik*                                       Organogenesis
  FOXD1                  MA0031.1    6                         *Ankrd37, Cadps2, Pdk1, Pygl, Tmprss6, 1700026L06Rik*                                                      Oxidative stress
  Spz1                   MA0111.1    6                         *Ak4, Cadps2, Slc16a3, Tmprss6, 1700026L06Rik, 2010300C02Rik*                                              Sex determination
  Nobox                  MA0125.1    6                         *Ankrd37, Cadps2, Pdk1, Selenbp1, Tmprss6, 2010300C02Rik*                                                  Organogenesis
  NFIL3                  MA0025.1    4                         *Cadps2, Pdk1, Selenbp1, 2010300C02Rik*                                                                    Immunity
  NFE2L2                 MA0150.1    4                         *Cadps2, Tmprss6, 1700026L06Rik, 2010300C02Rik*                                                            Oxidative stress
  Ddit3 Cebpa            MA0019.1    4                         *Bnip3, Cadps2, Pdk1, 1700026L06Rik*                                                                       Leukemia
  HNF4A                  MA0114.1    4                         *Cadps2, Pdk1, Pygl, Selenbp1*                                                                             Organogenesis
  Egr1                   MA0162.1    4                         *Ak4, Bnip3, Cadps2, Slc16a3*                                                                              ERK signaling
  HNF1A                  MA0046.1    3                         *Cadps2, Slc16a3, 2010300C02Rik*                                                                           Oxidative stress
  STAT1                  MA0137.2    3                         *Ankrd37, Cadps2, Slc16a3*                                                                                 Erythropoietin
